Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Seth P Lerner

Showing results (221-230 of 294) with videos related to

Pageof 30
Sort By:
European Urology Oncology|April 22, 2023
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314Yi-Tsung Lu, Melissa Plets, Gareth Morrison, et al.
Nature Reviews. Urology|September 10, 2025
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapiesLexiaochuan Wen, Hiroko Miyagi, Philippe E Spiess, et al.
European Urology|December 27, 2021
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder CancerMathieu Roumiguié, Ashish M Kamat, Trinity J Bivalacqua, et al.
The Journal of Urology|March 20, 2010
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patientsDerya Tilki, Oliver Reich, Robert S Svatek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerSeth P Lerner, David J McConkey, Catherine M Tangen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group StudyAnita L Sabichi, J Jack Lee, Robert J Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
European Urology|July 6, 2023
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
The Journal of Urology|July 21, 2009
p53 predictive value for pT1-2 N0 disease at radical cystectomyShahrokh F Shariat, Yair Lotan, Pierre I Karakiewicz, et al.
BJU International|September 11, 2025
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomyAdnan Fazili, Seyed Behzad Jazayeri, Kyle M Rose, et al.
Pageof 30

Showing results (221-230 of 294) with videos related to

Sort By:
Pageof 30
European Urology Oncology|April 22, 2023
Cell-free DNA Methylation as a Predictive Biomarker of Response to Neoadjuvant Chemotherapy for Patients with Muscle-invasive Bladder Cancer in SWOG S1314Yi-Tsung Lu, Melissa Plets, Gareth Morrison, et al.
Nature Reviews. Urology|September 10, 2025
Low-grade non-muscle-invasive bladder cancer: molecular landscape, treatment strategies and emerging therapiesLexiaochuan Wen, Hiroko Miyagi, Philippe E Spiess, et al.
European Urology|December 27, 2021
International Bladder Cancer Group Consensus Statement on Clinical Trial Design for Patients with Bacillus Calmette-Guérin-exposed High-risk Non-muscle-invasive Bladder CancerMathieu Roumiguié, Ashish M Kamat, Trinity J Bivalacqua, et al.
The Journal of Urology|March 20, 2010
Characteristics and outcomes of patients with clinical carcinoma in situ only treated with radical cystectomy: an international study of 243 patientsDerya Tilki, Oliver Reich, Robert S Svatek, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 15, 2023
Association of Molecular Subtypes with Pathologic Response, PFS, and OS in a Phase II Study of COXEN with Neoadjuvant Chemotherapy for Muscle-invasive Bladder CancerSeth P Lerner, David J McConkey, Catherine M Tangen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 13, 2006
Selenium accumulation in prostate tissue during a randomized, controlled short-term trial of l-selenomethionine: a Southwest Oncology Group StudyAnita L Sabichi, J Jack Lee, Robert J Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 11, 2021
A Randomized Phase II Study of Coexpression Extrapolation (COXEN) with Neoadjuvant Chemotherapy for Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
European Urology|July 6, 2023
Long-term Outcomes from a Phase 2 Study of Neoadjuvant Chemotherapy for Muscle-invasive Bladder Cancer (SWOG S1314; NCT02177695)Thomas W Flaig, Catherine M Tangen, Siamak Daneshmand, et al.
The Journal of Urology|July 21, 2009
p53 predictive value for pT1-2 N0 disease at radical cystectomyShahrokh F Shariat, Yair Lotan, Pierre I Karakiewicz, et al.
BJU International|September 11, 2025
Cisplatin-ineligible patients with muscle-invasive bladder cancer demonstrate poor long-term survival following immediate radical cystectomyAdnan Fazili, Seyed Behzad Jazayeri, Kyle M Rose, et al.
Pageof 30